The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer
Evelien W. Duiker(University Medical Center Groningen), Elisabeth G.E. de Vries(University Medical Center Groningen)
Cited by 54
Related Papers
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
|British Journal of Cancer|2007|231
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
|Cancer Discovery|2024|167
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
|Clinical Cancer Research|2025|3
Targeting the extrinsic apoptosis pathway in ovarian cancer
|University of Groningen research database (University of Groningen / Centre for Information Technology)|2008|0